



What's New

21.11.2016

NPPA requests Cipla Ltd. To furnish details along with all necessary documentary evidence in respect of Budesnide Inhalation 100mcg & 200mcg, Formoterol 6mcg + Budesonide 100mcg inhaler and Formoterlo 6mcg + Budesonide 200mcg inhaler Under Para 11(3).

NPPA has requested Cipla Ltd. To furnish details along with all necessary documentary evidence in respect of Budesnide Inhalation 100mcg & 200mcg, Formoterol 6mcg + Budesonide 100mcg inhaler and Formoterlo 6mcg + Budesonide 200mcg inhaler Under Para 11(3) referring Review Order No. 31015/27/2016-PI.I dated 22.6.2016.

NPPA has requested to provide the following information in respect of Budesnide Inhalation 100mcg & 200mcg, Formoterol 6mcg + Budesonide 100mcg inhaler and Formoterlo 6mcg + Budesonide 200mcg inhaler :

- (I) Whether there is any distortion noticed in the Ceiling prices of the mentioned formulations on account of the pack size, which may perhaps cause some of the packs to be non-remunerative or unviable compared to other pack sizes/single use-multi use.
- (II) Whether there is any special feature on any product which makes this formulation different from others on account of therapeutic benefit, and the rationale for the separate ceiling price.
- (III) Data/ information in respect of overcharging notice(s) issued by NPPA , if any, for the above mentioned formulations.

Cipla Ltd. Has been requested to furnish the above details as soon as possible along with all necessary documentary evidence in support of their contention to enable NPPA to take further necessary action.

["Review Order No 31015/27/2016-PI.I dated 22.6.2016 in respect of Budesnide Inhalation 100mcg & 200mcg, Formoterol 6mcg+ BUdesonide 100mcg inhaler and Formoterlo 6mcg+Budesonide 200mcg inhaler](#)